Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | HRH2 | P25021 | 3/20 | 0.39 |
| ▸ | HRH1 | P35367 | 3/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5965684 | 0.86 | SIGMAR1 (0.42) | SIGMAR1HRH3DRD2DRD3HRH2 | |
| SCHEMBL6199791 | 0.84 | USP30 (0.43) | HRH3HRH2HRH1USP30 | |
| SCHEMBL6094143 | 0.83 | HRH3 (0.57) | HRH3DRD2DRD3HRH2HRH1 | |
| SCHEMBL6093289 | 0.82 | CHRNA7 (0.40) | HRH3HRH2HRH1TBK1AR | |
| SCHEMBL7244317 | 0.82 | HRH3 (0.40) | HRH3DRD2DRD3HRH2HRH1 | |
| SCHEMBL6093979 | 0.82 | AR (0.41) | HRH3DRD2DRD3HRH2HRH1 | |
| SCHEMBL6093121 | 0.81 | HRH3 (0.40) | HRH3DRD2DRD3HRH2HRH1 | |
| SCHEMBL6094564 | 0.80 | DRD2 (0.51) | HRH3DRD2DRD3HRH2HRH1 | |
| SCHEMBL6097401 | 0.79 | CHRNA7 (0.41) | HRH3DRD2DRD3HRH2HRH1 | |
| SCHEMBL6095202 | 0.79 | USP30 (0.43) | DRD2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144914-B2 | 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-05 | — | — | US | disclosed |
| EP-1360187-B1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, CACNA1E | SIGMAR1 1091/4885HRH3 3033/4885DRD2 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.